A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
Stopped early · Phase 2
Conditions studied: Solid Tumors
In brief
The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.
Key facts
- Study ID
- NCT03926143
- Run by
- Bayer
- People needed
- 9
- Starts
- 2019-06-03
- Expected to finish
- 2022-05-18
- Last updated by the study team
- 2023-08-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants ongoing in an applicable Bayer-sponsored anetumab ravtansine parent study at the time of its planned study closure.
- For on-treatment participants: participant is eligible to receive the next dose of study intervention per the parent study protocol.
- For on-treatment participants: any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption. For applicable studies: should treatment be permanently interrupted in the parent study, participants may be enrolled in the follow-up portion of the rollover study.
You may not qualify if…
- For on-treatment participants: a positive serum pregnancy test.
- For on-treatment participants: use of one or more of the prohibited medications listed in the respective parent study protocol.
- Participants who are receiving standard-of-care agent(s) but not anetumab ravtansine in the parent study, and are able to receive standard-of-care agent outside of the clinical study.
Where it is running
- University of Chicago — Chicago, Illinois, United States
- National Cancer Institute - Maryland — Bethesda, Maryland, United States
- Sarah Cannon Cancer Center — Nashville, Tennessee, United States
- Mary Crowley Medical Research Center — Dallas, Texas, United States
- Hôpital de la Timone - Marseille — Marseille, France
- ASST Grande Ospedale Metropolitano Niguarda — Milan, Lombardy, Italy
- Samodzielny Publiczny Wojewodzki Szpital Zespolony — Szczecin-Zdunowo, Poland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.